Les informations fournies par GHD, sous quelque forme que ce soit, ne visent pas à remplacer les avis médicaux, mais servent plutôt de guide et de plate-forme d’information sur les divers traitements et options disponibles. L'utilisation de toute information fournie par le site internet de GHD, ses employés, ses consultants ou toute autre personne en son nom est à vos propres risques et discrétion.

© 2020 de Global Healthcare Direct Limited

CAR T-Cell Immunotherapy for Recurrent/Refractory Acute Myeloid Leukemia (AML) 

Phase I/II Clinical Trial

Patients with relapsed or refractory acute myeloid leukemia (AML) often develop resistance to chemotherapy. For this reason, the investigators are attempting to use T-cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR) to CD123, expressed on the surface of the cell in patients with CD123+ AML. The CAR enables the T-cell to recognize and kill the cell through the recognition of CD123, a protein expressed on the surface of the cell in patients with CD123+ leukemia. This is a Phase I/II study designed to evaluate the safety and efficacy of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of CD123+ leukemia.

Phase I/II Open Clinical Trial 

Through both our partner hospitals in Beijing and the trial sponsor, Hebei Senlang BIOTECHNOLOGY Co., LTD, we at Global Healthcare Direct gained a direct access to the clinical trial recruitment process. 

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 100 participants
Intervention Model Description: Single Group Assignment
Masking: Open-label trial
Primary Purpose: Treatment

How to apply for the Acute Myeloid Leukemia (AML) CAR-T trial?

Fill in the below form. Add a short description of your case history and of your current condition. Our case manager will contact you shortly and guide you through.

Choosing to participate in a medical trial is an important personal decision.

Talk with your doctors and family members or friends about deciding to join a study!

Joindre un fichier +
Taille max du fichier 25MB

Inclusion Criteria

(The results of the examination after patients admitted in hospital are the mainly criteria for admission)

  • Be diagnosed a kind of Relapsed or Refractory CD123+ AML;

  • ECOG score≤2;

  • To be aged 3 to 70 years;

  • More than a month lifetime from the consent signing date.


Exclusion Criteria

  • Serious cardiac insufficiency, left ventricular ejection fraction<50%;

  • Has a history of severe pulmonary function damaging;

  • Merging other progressing malignant tumor;

  • Merging uncontrolled infection;

  • Merging the metabolic diseases (except diabetes);

  • Merging severe autoimmune diseases or immunodeficiency disease;

  • Patients with active hepatitis B or hepatitis C;

  • Patients with HIV infection;

  • Has a history of serious allergies on Biological products (including antibiotics);

  • Pregnancy or lactation women;

  • Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.

* The Criteria is finally evaluated by Investigators.

Et après ?


1.Contactez-nous: remplissez ce formulaire, envoyez un email ou appelez-nous.

2.Notre responsable de cas vous enverra un questionnaire sur les essais hospitaliers et vous assistera avec tous les documents médicaux nécessaires.

3.Nous vérifierons toutes les options et vous fournirons les plans de traitement et les prix. Nous vous aiderons à choisir la meilleure option.

4.Sur demande, nous pouvons vous aider à organiser vos vols et votre hébergement.

5.Notre accompagnateur personnel vous attendra à la porte des arrivées et vous accompagnera tout au long de votre traitement.

6.Nous vous ferons parvenir les documents de sortie traduits et resterons en contact avec vous après votre départ.


Toujours là pour vous,

L'équipe GHD

Joindre un fichier +
Taille max du fichier 25MB